Skip to Main Content

Eli Lilly’s experimental migraine drug has performed well in three late-stage trials, shaving down the number of headache days per month — and pushing the drug forward in a competitive race to approval.

Patients who took the drug had about two fewer days of migraine headaches each month compared to placebo, the company said in a release. The antibody drug, galcanezumab, works by blocking the CGRP protein, which is linked to the painful, debilitating headaches that are a hallmark of migraines. Lilly plans on submitting an application for Food and Drug Administration approval later this year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!